Every recall we track for Wells Pharma of Houston LLC — 8 in all — plus the complaints and injury reports the public filed about them.
Wells Pharma recalls fentanyl citrate injectable solution due to cGMP deviations. Affected lots: NDC 73702-202-15, Lot 020226202150202. Expired May 2026.
Wells Pharma recalls phenylephrine hydrochloride injectable solution (40mg, 250mL) manufactured with cGMP deviations. Affected units have specific NDC and expiration dates listed in the recall notice.
Wells Pharma recalls fentanyl injectable solution (NDC 73702-204-25) manufactured with cGMP deviations. Affected lots may pose quality risks.
Wells Pharma recalls fentanyl citrate injectable solution (NARCOTIC, Cii) due to cGMP deviations. Products with specific NDC numbers and expiration dates are affected. Consumers should contact Wells Pharma for details.
Wells Pharma recalls fentanyl citrate injectable solution due to cGMP deviations. Affected products have specific NDC numbers and expiration dates. Consumers should contact the manufacturer for details.
Wells Pharma recalls fentanyl citrate injectable solution due to cGMP deviations. Affected lots: 022326203650432. Expired June 2026. No remedy specified in recall notice.
Wells Pharma recalls Ketamine Hydrochloride Injectable Solution due to cGMP deviations. This may affect safety and quality of the product. Check product details to see if you have the recalled batch.
Wells Pharma recalls ceFAZolin sodium in sterile water for injection due to lack of sterility assurance. This injectable solution (1g/10mL) may contain harmful bacteria. Affected lots: NDC 73702-131-10, Lot # 11092313110#01, Exp 01/12/24.
